NCT00588003View on ClinicalTrials.gov

Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Breast Cancer
Interventions
DRUG

anastrozole

anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.

OTHER

Placebo

No medication before surgery

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00588003 - Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer | Biotech Hunter | Biotech Hunter